Login to Your Account



Early Nod for Abiraterone, No Threat to Dendreon's Provenge

By Jennifer Boggs


Friday, April 29, 2011
Almost exactly a year after Dendreon Corp. set the prostate cancer space abuzz with the approval of immunotherapy Provenge (sipuleucel-T), Centocor Ortho Biotech Inc. scored another win with an FDA nod for abiraterone, an oral androgen biosynthesis inhibitor, roughly two months ahead of schedule.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription